Author

Kimberly Alarcon

Oregon Health & Science University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Synthetic Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Approach:experimental assay· 1 Assay:proteomics· 1

Frequent Co-Authors

Abigail B. VenturaiD· 1 shared Adel KardoshiD· 1 shared Alex MoreheadiD· 1 shared Alexander SmithiD· 1 shared Allison CreasoniD· 1 shared Amber Brown· 1 shared Amir Shanehsazzadeh· 1 shared Andrea K. SteigeriD· 1 shared

Activity by Year

2023-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperSynthetic Biology

Abigail B. VenturaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathway

Motoyuki Tsuda, Dove J. Keith, Colin J. Daniel, Carl Pelz, Katie E. Blise, Tugba Y. Ozmen, Furkan Ozmen, Kevin Hawthone, Jennifer R. Eng, Xi Li, Xiaoyan Wang, Hayley Zimny, Shamilene Sivagnanam, Konjit Betre, Nell C. Kirchberger, , Rosalie C. Sears

The paper identifies resistance mechanisms to KRAS-MEK pathway targeting in PDAC by analyzing clinical trial data and multi-omics profiles, showing that KRAS/MYC co-gain correlates with resistance and that co-targeting these genes is synergistic.

bioRxiv · Dec 15, 2025 · PreprintCancer Biology

Unlocking de novo antibody design with generative artificial intelligence

Amir Shanehsazzadeh, Matt McPartlon, George W. Kasun, Andrea K. Steiger, John M. Sutton, Edriss Yassine, Cailen M. McCloskey, Robel Gemechu Haile, Richard W. Shuai, Julian Alverio, Goran Rakočević, Simon Levine, Jovan Cejovic, Jahir M. Gutierrez, Alex Morehead, , Sharrol T. Bachas

Deep generative models combined with high-throughput screening design de novo anti-HER2 antibodies without further optimization, yielding nanomolar binders functionally comparable or superior to trastuzumab.

bioRxiv · Jan 8, 2023 · PreprintSynthetic Biology